Biochem/physiol Actions
Triple reuptake inhibitor (TRI); serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI); IC50 values of ~20, 14, and 78 nM, respectively.
Features and Benefits
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
- UPC:
- 42251703
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- D6446-5MG